Showing results (31-40 of 41) with videos related to
Sort By:
Pageof 5
Clinical Immunology (Orlando, Fla.)|March 9, 2018
Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteersKent J Weinhold, Jack F Bukowski, Todd V Brennan, et al.Cell|January 30, 2016
Parsing the Interferon Transcriptional Network and Its Disease AssociationsSara Mostafavi, Hideyuki Yoshida, Devapregasan Moodley, et al.Bioorganic & Medicinal Chemistry|November 14, 2007
Benzenesulfonamide indole inhibitors of cytosolic phospholipase A2alpha: optimization of in vitro potency and rat pharmacokinetics for oral efficacyKatherine L Lee, Mark L Behnke, Megan A Foley, et al.Journal of Medicinal Chemistry|February 20, 2007
Discovery of Ecopladib, an indole inhibitor of cytosolic phospholipase A2alphaKatherine L Lee, Megan A Foley, Lihren Chen, et al.Bioorganic & Medicinal Chemistry|April 8, 2020
Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1Andrew Fensome, Catherine M Ambler, Eric Arnold, et al.Journal of Medicinal Chemistry|August 14, 2020
Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune DiseasesBrian S Gerstenberger, Catherine Ambler, Eric P Arnold, et al.Arthritis and Rheumatism|May 28, 2010
Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in miceTsung H Lin, Martin Hegen, Elizabeth Quadros, et al.Journal of Medicinal Chemistry|May 24, 2008
Indole cytosolic phospholipase A2 alpha inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic acid, efipladibJohn C McKew, Katherine L Lee, Marina W H Shen, et al.ACS Chemical Biology|October 30, 2016
Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective InhibitionJean-Baptiste Telliez, Martin E Dowty, Lu Wang, et al.Journal of Medicinal Chemistry|August 17, 2018
Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)Andrew Fensome, Catherine M Ambler, Eric Arnold, et al.Pageof 5